Do cannabinoids have a therapeutic role in transplantation?

Trends in Pharmacological Sciences

Volumn 31, Issue 8, 2010, Pages 345-350

  Nagarkatti, Mitzi ^a   Rieder, Sadiye Amcaoglu ^a   Hegde, Venkatesh L ^a   Kanada, Shunsuke ^a   Nagarkatti, Prakash ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ALEMTUZUMAB; BASILIXIMAB; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CYCLOSPORIN; DACLIZUMAB; ENDOCANNABINOID; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; LYMPHOCYTE ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; OKT 3; TACROLIMUS; TETRAHYDROCANNABINOL; THYMOCYTE ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CELL DEATH; CELL METABOLISM; CYTOKINE PRODUCTION; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INHIBITION KINETICS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; BLOOD-BRAIN BARRIER; CANNABINOIDS; ENDOCANNABINOIDS; GRAFT REJECTION; HUMANS; ORGAN TRANSPLANTATION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 77955266826     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.05.006     Document Type: Article

References (69)

1. Matsuda L.A., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
2. Munro S., et al. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
3. Wagner J.A., et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur. J. Pharmacol. 2001, 423:203-210.
4. Kaminski N.E., et al. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 1992, 42:736-742.
5. Galiegue S., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232:54-61.
6. Devane W.A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
7. Mechoulam R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50:83-90.
8. Sugiura T., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215:89-97.
9. Bisogno T., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 2001, 134:845-852.
10. Zygmunt P.M., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
11. Malfait A.M., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9561-9566.
12. Mestre L., et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell Neurosci. 2009, 40:258-266.
13. Sanchez A.J., et al. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem. Pharmacol. 2006, 72:1697-1706.
14. Sumariwalla P.F., et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 2004, 50:985-998.
15. Hegde V.L., et al. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 2008, 74:20-33.
16. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 2003, 3:745-755.
17. Lombard C., et al. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. 2007, 122:259-270.
18. Eisenstein T.K., et al. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J. Neuroimmunol. 2007, 189:17-22.
19. Morris P.J. Transplantation-a medical miracle of the 20th century. N. Engl. J. Med. 2004, 351:2678-2680.
20. Sayegh M.H., Carpenter C.B. Transplantation 50 years later-progress, challenges, and promises. N. Engl. J. Med. 2004, 351:2761-2766.
21. Appelbaum F.R. Haematopoietic cell transplantation as immunotherapy. Nature 2001, 411:385-389.
22. Ferrara J.L., Deeg H.J. Graft-versus-host disease. N. Engl. J. Med. 1991, 324:667-674.
23. Simpson D. New developments in the prophylaxis and treatment of graft versus host disease. Expert Opin. Pharmacother. 2001, 2:1109-1117.
24. Ho S., et al. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996, 80:S40-S45.
25. Flechner S.M., et al. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin. Transplant. 2008, 22:1-15.
26. Rieder S.A., et al. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 2009, [E-pub ahead of print. PMID:19457575].
27. Zhu W.H., et al. Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 1998, 286:1103-1109.
28. McKallip R.J., et al. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 2002, 302:451-465.
29. Bidinger B., et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin. Immunol. 2003, 108:95-102.
30. Lee C.Y., et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int. Immunopharmacol. 2008, 8:732-740.
31. Howlett A.C., et al. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1998, 33:297-302. (PMID: 3352594).
32. Kaminski N.E. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J. Neuroimmunol. 1998, 83:124-132.
33. Snijdewint F.G., et al. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 1993, 150:5321-5329.
34. Crocker I.C., et al. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996, 31:223-235.
35. Tokoyoda K., et al. Up-regulation of IL-4 production by the activated cAMP/cAMP-dependent protein kinase (protein kinase A) pathway in CD3/CD28-stimulated naive T cells. Int. Immunol. 2004, 16:643-653.
36. Klein T.W., et al. The cannabinoid system and cytokine network. Proc. Soc. Exp. Biol. Med. 2000, 225:1-8.
37. Baldwin G.C., et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am. J. Respir. Crit. Care Med. 1997, 156:1606-1613.
38. Srivastava M.D., et al. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998, 40:179-185.
39. Di Filippo C., et al. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J. Leukoc. Biol. 2004, 75:453-459.
40. Selvi E., et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 2008, 26:574-581.
41. Klein T.W., et al. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J. Immunol. 2000, 164:6461-6466.
42. Zhu W., et al. Delta 9-Tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. J. Pharmacol. Exp. Ther. 1994, 270:1334-1339.
43. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5:400-411.
44. Littman, D.R. and Rudensky, A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140, 845-858.
45. Belkaid Y., Tarbell K. Regulatory T cells in the control of host-microorganism interactions. Annu. Rev. Immunol. 2009, 27:551-589.
46. Long E., Wood K.J. Regulatory T cells in transplantation: transferring mouse studies to the clinic. Transplantation 2009, 88:1050-1056.
47. Yong Z., et al. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl. Immunol. 2007, 17:120-129.
48. Kaplan B.L., et al. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J. Leukoc. Biol. 2005, 77:966-974.
49. Rockwell C.E., Kaminski N.E. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J. Pharmacol. Exp. Ther. 2004, 311:683-690.
50. Sancho R., et al. Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol. Pharmacol. 2003, 63:429-438.
51. Cines D.B., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
52. Al-Lamki R.S., et al. Endothelial cells in allograft rejection. Transplantation 2008, 86:1340-1348.
53. Hornick P.I., et al. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998, 97:1257-1263.
54. Kalil J., et al. Humoral rejection in two HLA identical living related donor kidney transplants. Transplant. Proc. 1989, 21:711-713.
55. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365:1570-1576.
56. Rajesh M., et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2210-H2218.
57. Rajesh M., et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H610-H619.
58. Batkai S., et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 2007, 21:1788-1800.
59. Rajnoch J., Viklicky O. Angiogenesis and organ transplantation. Folia Microbiol. (Praha) 2004, 49:499-505.
60. Schley M., et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res. Bull. 2009, 79:333-337.
61. Elsohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005, 78:539-548.
62. Ranney D.N., et al. Marijuana use in potential liver transplant candidates. Am. J. Transplant. 2009, 9:280-285.
63. Koch M., Banys P. Liver transplantation and opioid dependence. JAMA 2001, 285:1056-1058.
64. Bright R.P. Denial of hepatic transplantation on the basis of smoking: is it ethical?. Curr. Opin. Organ Transplant. 2010, 15:249-253. (PMID: 20154621).
65. Lombard C., et al. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk. Res. 2005, 29:915-922.
66. Schulz T.F. Cancer and viral infections in immunocompromised individuals. Int. J. Cancer 2009, 125:1755-1763.
67. McKallip R.J. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J. Immunol. 2005, 174:3281-3289.
68. Fegley D., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 2005, 313:352-358.
69. Cravatt B.F., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9371-9376.